Cumberland Pharmaceuticals (NASDAQ:CPIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

CPIX opened at $1.48 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.37 and a quick ratio of 1.21. The company has a market cap of $21.00 million, a price-to-earnings ratio of -2.51 and a beta of 0.23. The firm has a 50 day simple moving average of $1.50 and a 200 day simple moving average of $1.74. Cumberland Pharmaceuticals has a fifty-two week low of $1.38 and a fifty-two week high of $2.36.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 21.67% and a positive return on equity of 0.21%. The company had revenue of $8.50 million during the quarter.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.